ES2060775T3 - Egf para la prevencion de daños en tejidos despues de un episodio isquemico. - Google Patents

Egf para la prevencion de daños en tejidos despues de un episodio isquemico.

Info

Publication number
ES2060775T3
ES2060775T3 ES89307909T ES89307909T ES2060775T3 ES 2060775 T3 ES2060775 T3 ES 2060775T3 ES 89307909 T ES89307909 T ES 89307909T ES 89307909 T ES89307909 T ES 89307909T ES 2060775 T3 ES2060775 T3 ES 2060775T3
Authority
ES
Spain
Prior art keywords
egf
prevention
tissue damage
ischemic episode
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89307909T
Other languages
English (en)
Inventor
Warren D Sheffield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ethicon Inc
Original Assignee
Ethicon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethicon Inc filed Critical Ethicon Inc
Application granted granted Critical
Publication of ES2060775T3 publication Critical patent/ES2060775T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PROPORCIONA UN METODO PARA EVITAR EL DETERIORO DE LOS TEJIDOS EN UN PACIENTE, DESPUES QUE EL TEJIDO HA SIDO PRIVADO DEL APORTE DE SANGRE QUE RESULTA EN ISQUEMIA. EL METODO CONSISTE EN ADMINISTRAR AL PACIENTE UN POLIPEPTIDO QUE TIENE ACTIVIDAD DE FACTOR DE CRECIMIENTO EPIDERMICO, O ACTIVIDAD DE FACTOR DE CRECIMIENTO DE FIBROBLASTO, ANTES O DESPUES DEL SUCESO ISQUEMICO.
ES89307909T 1988-08-03 1989-08-03 Egf para la prevencion de daños en tejidos despues de un episodio isquemico. Expired - Lifetime ES2060775T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/227,579 US5057494A (en) 1988-08-03 1988-08-03 Method for preventing tissue damage after an ischemic episode

Publications (1)

Publication Number Publication Date
ES2060775T3 true ES2060775T3 (es) 1994-12-01

Family

ID=22853654

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89307909T Expired - Lifetime ES2060775T3 (es) 1988-08-03 1989-08-03 Egf para la prevencion de daños en tejidos despues de un episodio isquemico.

Country Status (8)

Country Link
US (1) US5057494A (es)
EP (1) EP0357240B1 (es)
JP (1) JP2921870B2 (es)
AU (1) AU623423B2 (es)
CA (1) CA1332351C (es)
DE (1) DE68911068T2 (es)
ES (1) ES2060775T3 (es)
ZA (1) ZA895910B (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2814529B2 (ja) * 1989-03-16 1998-10-22 味の素株式会社 虚血性脳障害治療薬
US5200176A (en) * 1989-10-06 1993-04-06 Genentech, Inc. Method for protection of ischemic tissues using tumor nerosis factor
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
IT1240683B (it) * 1990-04-26 1993-12-17 Zambon Spa Composizione farmaceutica contenente egf
US5434135A (en) * 1990-08-02 1995-07-18 Indu Parikh Growth factor compositions, preparation and use
JPH06501695A (ja) * 1990-10-01 1994-02-24 ブリガム・アンド・ウイメンズ・ホスピタル 主要血管事象を抑制するためのベータ−カロテン及びビタミンｅ療法
CA2092718C (en) * 1990-10-25 2007-08-07 Grace H. W. Wong Use of protective agents against reactive oxygen species
GR1002610B (el) * 1991-01-02 1997-02-20 Johnson & Johnson Consumer Products Inc. Θεραπευτικες συνθεσεις πληγων που περιεχουν παραγοντα αναπτυξης ινοβλαστων και ασκορβικον οξυ.
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
SE9101840L (sv) * 1991-06-14 1992-12-15 Kabi Pharmacia Ny medicinsk anvaendning
WO1993008828A1 (en) * 1991-11-08 1993-05-13 Syntex-Synergen Neuroscience Joint Venture Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
AU659723B2 (en) * 1992-02-14 1995-05-25 Kaken Pharmaceutical Co., Ltd. Remedy for airway diseases
CA2061567C (en) * 1992-02-20 1998-02-03 Rudolf E. Falk Use of hyaluronic acid to repair ischemia reperfusion damage
ES2061380B1 (es) * 1992-11-23 1995-07-01 Boehringer Ingelheim Espana Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores.
AU6409594A (en) * 1993-03-16 1994-10-11 Alliance Pharmaceutical Corporation Preservation solution and method for warm organ preservation
WO1995003843A1 (en) * 1993-07-30 1995-02-09 The Regents Of The University Of California Endocardial infusion catheter
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
US5449671A (en) * 1993-09-29 1995-09-12 Alcon Laboratories, Inc. Use of TGF-β3, to prevent or retard fistula closure following glaucoma filtration surgery
US5411940A (en) * 1993-09-29 1995-05-02 Alcon Laboratories, Inc. Use of TGF-β3 to reduce the formation of scar tissue in response to corneal trauma
ATE306903T1 (de) 1995-03-24 2005-11-15 Genzyme Corp Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren
EP0894004B2 (en) 1996-03-22 2007-02-21 Curis, Inc. Method for enhancing functional recovery of motor coordination, speech or sensory perception after central nervous system ischemia or trauma
US20030113271A1 (en) * 1997-01-29 2003-06-19 University Technology Corporation Formulations for pulmonary delivery
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
US6123956A (en) * 1997-07-10 2000-09-26 Keith Baker Methods for universally distributing therapeutic agents to the brain
US6191109B1 (en) 1997-10-31 2001-02-20 Children's Hospital, Inc. Methods of treating intestinal ischemia using heparin-binding epidermal growth factor
EP1109572A4 (en) * 1998-09-03 2004-11-24 Neuronz Ltd NEUROPROTECTION
US7112570B2 (en) 2000-08-24 2006-09-26 Neuren Pharmaceuticals, Ltd. GPE analogs
WO2002022163A1 (en) 2000-09-13 2002-03-21 Chugai Seiyaku Kabushiki Kaisha Remedies for ischemic diseases
CU23157A1 (es) * 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
WO2002087580A1 (en) * 2001-04-25 2002-11-07 Takeda Chemical Industries, Ltd. Abc expression promoters
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
EP1401808B1 (en) 2001-05-24 2009-07-08 Neuren Pharmaceuticals Limited Gpe analogs and peptidomimetics
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
US20050009788A1 (en) * 2002-07-29 2005-01-13 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling connexin 43 expression
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
CN101845009B (zh) 2002-07-29 2012-10-03 卡达克斯药物公司 用于抑制和改善疾病的类胡萝卜素结构类似物
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US7723327B2 (en) * 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US7763649B2 (en) * 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US7345091B2 (en) * 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US7320997B2 (en) * 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
WO2004017959A2 (en) * 2002-08-22 2004-03-04 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
US20040044220A1 (en) * 2002-08-22 2004-03-04 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
CA2564066A1 (en) * 2004-04-14 2005-11-03 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
WO2008134635A1 (en) 2007-04-30 2008-11-06 Nationwide Children's Hospital Heparin binding epidermal growth factor (hb-egf) for use in methods of treating and preventing intestinal injury related to hemorrhagic shock and resuscitation
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
US10702226B2 (en) 2015-08-06 2020-07-07 Covidien Lp System and method for local three dimensional volume reconstruction using a standard fluoroscope
US10716525B2 (en) 2015-08-06 2020-07-21 Covidien Lp System and method for navigating to target and performing procedure on target utilizing fluoroscopic-based local three dimensional volume reconstruction
US10674982B2 (en) 2015-08-06 2020-06-09 Covidien Lp System and method for local three dimensional volume reconstruction using a standard fluoroscope
US11529190B2 (en) 2017-01-30 2022-12-20 Covidien Lp Enhanced ablation and visualization techniques for percutaneous surgical procedures
US11793579B2 (en) 2017-02-22 2023-10-24 Covidien Lp Integration of multiple data sources for localization and navigation
US10699448B2 (en) 2017-06-29 2020-06-30 Covidien Lp System and method for identifying, marking and navigating to a target using real time two dimensional fluoroscopic data
EP3694412B1 (en) 2017-10-10 2025-12-31 Covidien LP SYSTEM AND METHOD FOR IDENTIFYING AND MARKING A TARGET IN A THREE-DIMENSIONAL FLUOROSCOPIC RECONSTRUCTION
US11364004B2 (en) 2018-02-08 2022-06-21 Covidien Lp System and method for pose estimation of an imaging device and for determining the location of a medical device with respect to a target
US11705238B2 (en) 2018-07-26 2023-07-18 Covidien Lp Systems and methods for providing assistance during surgery
US11877806B2 (en) 2018-12-06 2024-01-23 Covidien Lp Deformable registration of computer-generated airway models to airway trees
US11801113B2 (en) 2018-12-13 2023-10-31 Covidien Lp Thoracic imaging, distance measuring, and notification system and method
US11617493B2 (en) 2018-12-13 2023-04-04 Covidien Lp Thoracic imaging, distance measuring, surgical awareness, and notification system and method
US11357593B2 (en) 2019-01-10 2022-06-14 Covidien Lp Endoscopic imaging with augmented parallax
US11625825B2 (en) 2019-01-30 2023-04-11 Covidien Lp Method for displaying tumor location within endoscopic images
US11744643B2 (en) 2019-02-04 2023-09-05 Covidien Lp Systems and methods facilitating pre-operative prediction of post-operative tissue function
US11627924B2 (en) 2019-09-24 2023-04-18 Covidien Lp Systems and methods for image-guided navigation of percutaneously-inserted devices
US12102298B2 (en) 2019-12-10 2024-10-01 Covidien Lp Lymphatic system tracking
US12161309B2 (en) 2020-09-24 2024-12-10 Covidien Lp Articulating mechanism for the laparoscopic ablation device for blunt dissection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE474981A (es) * 1940-02-20
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction
US4766073A (en) * 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
DE10120467A1 (de) * 2001-04-26 2002-10-31 Bosch Gmbh Robert Wischblatt zum Reinigen von Scheiben, insbesondere von Kraftfahrzeugen

Also Published As

Publication number Publication date
JPH0283334A (ja) 1990-03-23
DE68911068D1 (de) 1994-01-13
JP2921870B2 (ja) 1999-07-19
EP0357240A2 (en) 1990-03-07
EP0357240B1 (en) 1993-12-01
ZA895910B (en) 1991-04-24
EP0357240A3 (en) 1991-07-24
US5057494A (en) 1991-10-15
AU3924489A (en) 1990-02-08
CA1332351C (en) 1994-10-11
AU623423B2 (en) 1992-05-14
DE68911068T2 (de) 1994-06-30

Similar Documents

Publication Publication Date Title
ES2060775T3 (es) Egf para la prevencion de daños en tejidos despues de un episodio isquemico.
DE3851776D1 (de) Verwendung von IGF-II zur Behandlung von Knochenkrankheiten.
ES2063011T3 (es) Agentes antibacteriales de quinolonas y naftiridinas que contienen un alfa-aminoacido en la cadena lateral del 7-sustituyente.
DE3382458D1 (de) Haarwuchsmittel.
MX161342A (es) Procedimiento para el tratamiento de tejido colagenoso adaptado como implante prostetico
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
DE3872372D1 (de) Zusammensetzung zur erhoehung der intrazell-atp-spiegel und des physischen leistungsniveaus und zur erhoehung der geschwindigkeit von wundenheilung.
MX170454B (es) Una composicion para cicatrizacion de heridas y regeneracion de huesos y metodo para prepararla
DE69029257D1 (de) Anordnung zur bestrahlung von laserstrahlen
DE3752112D1 (de) Verwendung von Inositoltriphosphat zur Behandlung von Entzündungen
ES2084579T3 (es) Uso de buspirona en la preparacion de una composicion farmaceutica para el tratamiento del abuso del alcohol.
DE59007531D1 (de) Verwendung des Wirkstoffs Azelastin zur Bekämpfung von Psoriasis-Erkrankungen.
ES2073678T3 (es) Formulaciones radiofarmaceuticas, su metodo de administracion y procedimiento de preparacion.
ATE96329T1 (de) Topisch anwendbare pharmazeutische zubereitung.
ES2032888T3 (es) Productos conservados para la limpieza del cabello y el cuerpo y utilizacion de una combinacion de sustancias conservantes.
ES2038359T3 (es) Procedimiento para la obtencion de formulaciones inyectables intramusculares de inhibidores de girasa.
ES2052583T3 (es) Derivados de peptidos relacionados con el gel calcitonina.
ES2106031T3 (es) Una composicion comprendiendo un factor de crecimiento, su metodo de obtencion y uso.
ES2133289T3 (es) Aumento en los niveles de glutation con glutamina.
ES2041705T3 (es) Procedimiento para la preparacion de 1-(4-hidroxi-3,5-di-terc-butil-benzoil)-homopiperazina y sus derivados.
IT8349477A0 (it) Procedimento per la conservazione di tessuto organico vivo mediante congelamento
ES2052761T3 (es) Nuevos esteres del acido androstano 17-carboxilico, procedimiento para su preparacion y medicamento que los contiene.
ATE126061T1 (de) Verwendung von lithium zur behandlung oder prophylaxe von molluscum contagiusum.
ES2091249T3 (es) Analogos de iludina utilizables como agentes antitumorales.
DE69133077D1 (de) Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 357240

Country of ref document: ES